Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Amisulpride, neuroleptic and antinegative action].

D Widlöcher1, J F Allilaire, A Guérard des Lauriers

  • 1Hôpital de la Salpêtrière, INSERM Unité 302, Service Psychiatrie Adultes, Paris.

L'Encephale
|March 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Attribution of mental States to others by schizophrenic patients.

Cognitive neuropsychiatry·2014
Same author

Improved ability to identify symptoms of major depressive disorder (MDD) in general practice.

International journal of psychiatry in clinical practice·2014
Same author

[Controlled drug consumption rooms].

Bulletin de l'Academie nationale de medecine·2014
Same author

[Traumatic neuroses. 1958].

L'Encephale·2010
Same author

Evaluating major depressive episodes through the algorithmically structured systematic exploration of subject's state of mind.

Psychopathology·2009
Same author

Semantic inhibition disorders in schizophrenic patients assessed by a lexical decision task.

European psychiatry : the journal of the Association of European Psychiatrists·2009

Amisulpride exhibits dual dose-dependent actions, effectively treating positive schizophrenia symptoms at high doses and negative symptoms at low doses. This selective dopamine D2 receptor antagonist offers rapid and well-tolerated therapeutic benefits.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Amisulpride is a substituted benzamide derivative with selective dopamine D2 receptor affinity.
  • It displays higher affinity for limbic/hippocampal receptors than striatal receptors.
  • This molecule exhibits distinct dose-dependent actions.

Purpose of the Study:

  • To investigate the dual pharmacological actions of amisulpride at different dose levels.
  • To evaluate its efficacy and tolerance in treating positive and negative symptoms of schizophrenia.
  • To compare its effects with conventional neuroleptics.

Main Methods:

  • Animal studies to assess hyperdopaminergic and hypodopaminergic symptomatology.
  • Open and double-blind clinical studies in patients with schizophrenia.

Related Experiment Videos

  • Dose-ranging studies for positive and negative symptom treatment.

    • Main Results:

    • High-dose amisulpride (600-1,200 mg/day) effectively treats positive schizophrenia symptoms without sedation.
    • Low-dose amisulpride (approx. 150 mg/day) improves negative schizophrenia symptoms.
    • Rapid onset of action (within 1 week) and good neurological tolerance observed.

    Conclusions:

    • Amisulpride's dose-related dissociation of effects provides a unique therapeutic profile.
    • It is effective for both positive and negative schizophrenia symptoms with superior tolerance compared to haloperidol.
    • The drug demonstrates rapid efficacy and favorable tolerability in clinical practice.